Mapping Authorized Technologies and Practice Realities
The landscape of AI in medical devices spans over 1600 authorized products regulated by federal oversight agencies. A comprehensive review of FDA authorizations reveals that 84.4% of AI medical devices utilize imaging data, while 14.5% analyze physiological signals such as electrocardiograms.1,2
Most current applications focus on patient assessment, but interventional tools such as automated insulin delivery systems demonstrate how software algorithms directly assist in active therapy management.2
Systematic reviews highlight that smart insulin pens can achieve over 95% accuracy in detecting proper injection sites, while smart pumps autonomously process glucose monitor trends to stabilize glycemic control.3
These technological advancements align with broader market expansion projections, which estimate the global AI health care sector will surpass $187 billion by 2030.
Despite this rapid expansion of automated devices, real-world adoption among pharmacy professionals remains cautious. A survey conducted among 122 pharmacists across New York hospital and specialty settings revealed that 61% reported moderate familiarity with AI tools.4
However, usage was predominantly restricted to administrative duties, including document proofreading at 50% and literature summarization at 44%, while only 3% utilized software for clinical decision support or order verification.
Although 55% of surveyed pharmacists agreed that AI could potentially reduce medication errors, 82% cited information accuracy as a major concern, 79% pointed to a lack of clinical judgment, and 61% raised data privacy risks.4
Strengthening Risk Feedback Loops and Future Integration
To bridge the gap between technological potential and clinical safety, pharmacists occupy a pivotal position in post-market risk management. As accessible health care providers, pharmacists receive direct feedback from patients regarding device alerts, interface difficulties, and operational confusion.
Reporting these recurring operational observations back to device manufacturers enables developers to refine instructions, resolve interface issues, and enhance overall safety profiles.
Looking ahead, the health care industry anticipates a rise in home monitoring technologies, personalized therapeutic software, and eventually, autonomous agentic systems once standardized testing protocols are established. Survey data indicates that 77% of practicing pharmacists are willing to adopt AI tools if validated institutionally, while 89% advocate for integrating AI education directly into professional curricula.4
Through structured training and active risk surveillance, pharmacists can safely guide patients through the expanding ecosystem of medical device technology.
Stay tuned for weekly podcast episodes of Over the Counter powered by